Moderna's Veteran Data and Cancer Timeline Collide With a $4 Billion Spending Bill
Published on 11/13/2026 at 20:31 | Editorial boerse-global.de
Moderna opened a two-front story for investors this week: fresh observational evidence that its newer COVID shot outperforms the original in older Americans, and a manufacturing and regulatory runway for a personalized cancer vaccine that won't reach the market until at least 2027. The stock slipped 3.0% on Wednesday, with press coverage tying the decline to the prior day's analyst event — higher spending expectations and the absence of formal guidance for the coming year.
What the veteran study actually shows
Published in JAMA Network Open, the analysis covered roughly 294,000 U.S. veterans aged 65 and older who were matched for comparison. Against medically treated COVID-19, mNEXSPIKE demonstrated a relative vaccine effectiveness of 35.9% versus Comirnaty. For COVID-related hospitalizations, the figure came in at 47.0%. Moderna describes the findings as an observed association between vaccination with mNEXSPIKE and protection relative to Comirnaty; the percentages represent relative efficacy in a direct head-to-head comparison of the two products.
The spending side of the ledger
At Tuesday's analyst day, Moderna put expected cash costs for next year at approximately $4 billion, with expanded oncology investment named as the principal driver. For 2027 through 2030, the company guided to roughly $4 billion to $4.5 billion annually. The missing piece — a formal forecast for the coming year — disappointed shareholders who had been looking for firmer targets, according to media reports, which also cited moderate headwinds from the broader market as an additional weight on the shares.
On November 6, Moderna had raised its expected full-year 2026 revenue growth to 15%–25%, up from a prior outlook of as much as 10%. Third-quarter 2026 revenue reached $1.3 billion, with GAAP net income of $0.2 billion.
Should investors sell immediately? Or is it worth buying Moderna?
A cancer vaccine with a date certain
The more consequential catalyst sits further out. Moderna and Merck plan to file the U.S. application for their personalized cancer vaccine Intismeran by the end of 2026, which would put a potential approval in 2027. The clinical case rests on a Phase III trial in high-risk melanoma: Intismeran plus Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone, while the risk of distant metastasis or death fell 38%, over a median follow-up of 24.6 months.
Behind the filing stands a manufacturing bet. The Marlborough facility is slated to become the global supply base in 2027, subject to regulatory clearance, and has been producing clinical-trial material since September 2025. Longer term, Moderna envisions capacity for tens of thousands of patients per year. Those plans give the investment case a tangible operational anchor — but they only convert into revenue once an approval and actual demand arrive.
Cash, timelines and the bridge to 2027
Moderna expects roughly $9 billion in cash, investments and unused credit lines at the end of 2026, a cushion that affords room to fund the pipeline provided outflows and program timing stay manageable. The risk scenario is straightforward: costs land on schedule while new revenue slips, stretching the period in which the company must self-finance development and commercialization.
A second commercial opportunity is the planned broader U.S. launch of the flu vaccine mFlusiva in the 2027/28 season; more than 110,000 shots were administered during its limited introduction. Whether either program becomes a durable revenue source depends on execution and demand.
The next hard checkpoint is the Intismeran filing by the end of 2026. Fourth-quarter 2026 results are due in February 2027, and with them the official annual forecast — the document that should finally show which revenue trajectory Moderna is setting against its investment plans. Until then, investors are left weighing a regulatory calendar, a $4 billion bill and a revenue outlook that stops at 2026.
Ad
Moderna Stock: New Analysis - 13 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
